Evolokumab: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
←Membuat halaman berisi ''''Evolokumab'''[6] adalah antibodi monoklonal yang merupakan obat imunoterapi untuk pengobatan hiperlipidemia. Evolocumab adalah antibodi monoklonal manusia yang menghambat proprotein konvertase subtilisin/kexin tipe 9 (PCSK9). PCSK9 adalah protein yang menargetkan reseptor LDL untuk degradasi; penghambatannya meningkatkan kemampuan hati untuk menghilangkan LDL-C, yang sering disebut sebagai kolesterol "jahat", dari darah.[7][8]' Tag: kemungkinan perlu dirapikan Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
Tidak ada ringkasan suntingan Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
||
Baris 1:
{{Infobox drug
| type = mab
| image =
| width =
| alt =
| caption =
<!-- Monoclonal antibody data -->
| mab_type = mab
| source = u
| target = [[PCSK9]]
<!-- Clinical data -->
| pronounce = e-voe-LOK-ue-mab
| tradename = Repatha
| Drugs.com = {{drugs.com|monograph|evolocumab}}
| MedlinePlus =
| DailyMedID = Evolocumab
| pregnancy_AU = B1
| pregnancy_AU_comment =
| pregnancy_category=
| routes_of_administration = [[Subcutaneous injection|Subcutaneous]]
| class =
| ATC_prefix = C10
| ATC_suffix = AX13
| ATC_supplemental =
<!-- Legal status -->
| legal_AU = S4
| legal_AU_comment = <ref>{{cite web | title=Prescription medicines: registration of new chemical entities in Australia, 2015 | website=Therapeutic Goods Administration (TGA) | date=21 June 2022 | url=https://www.tga.gov.au/prescription-medicines-registration-new-chemical-entities-australia-2015 | access-date=10 April 2023}}</ref>
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment =
| legal_CA = Rx-only
| legal_CA_comment = <ref>{{cite web | title=Health Canada New Drug Authorizations: 2015 Highlights | website=[[Health Canada]] | date=4 May 2016 | url=https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/health-canada-new-drug-authorizations-2015-highlights.html | access-date=7 April 2024}}</ref>
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment =
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment =
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment =
| legal_US = Rx-only
| legal_US_comment = <ref name="Repatha FDA label">{{cite web | title=Repatha- evolocumab injection, solution Repatha- evolocumab kit | work = DailyMed | publisher = U.S. National Library of Medicine | date=6 May 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd61e902-166d-4aa6-9f3c-a18c1008d07e | access-date=20 October 2020}}</ref>
| legal_EU = Rx-only
| legal_EU_comment = <ref>{{cite web | title=Repatha EPAR | website=European Medicines Agency | date=17 July 2015 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/repatha | access-date=29 June 2024}}</ref>
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment =
| legal_status = Rx-only
<!-- Pharmacokinetic data -->
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action =
| excretion =
<!-- Identifiers -->
| CAS_number_Ref =
| CAS_number = 1256937-27-5
| CAS_supplemental =
| PubChem =
| IUPHAR_ligand =
| DrugBank_Ref =
| DrugBank =
| ChemSpiderID_Ref =
| ChemSpiderID = none
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = LKC0U3A8NJ
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D10557
| ChEBI_Ref =
| ChEBI =
| ChEMBL_Ref =
| ChEMBL =
| NIAID_ChemDB =
| PDB_ligand =
| synonyms = AMG-145<ref name=sheridan2013>{{cite journal | vauthors = Sheridan C | title = Phase 3 data for PCSK9 inhibitor wows | journal = Nature Biotechnology | volume = 31 | issue = 12 | pages = 1057–1058 | date = December 2013 | pmid = 24316621 | doi = 10.1038/nbt1213-1057 | s2cid = 34214247 }}</ref>
<!-- Chemical and physical data -->
| IUPAC_name =
| C=6242 | H=9648 | N=1668 | O=1996 | S=56
| SMILES =
| StdInChI =
| StdInChI_comment =
| StdInChIKey =
| density =
| density_notes =
| melting_point =
| melting_high =
| melting_notes =
| boiling_point =
| boiling_notes =
| solubility =
| sol_units =
| specific_rotation =
}}
'''Evolokumab'''<ref>{{cite journal | vauthors = ((World Health Organization)) | year = 2013 | title = International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 70 | journal = WHO Drug Information | volume = 27 | issue = 3 | hdl = 10665/331167 | hdl-access = free | author-link = World Health Organization }}</ref> adalah antibodi monoklonal yang merupakan obat imunoterapi untuk pengobatan hiperlipidemia.
Evolocumab adalah antibodi monoklonal manusia yang menghambat proprotein konvertase subtilisin/kexin tipe 9 (PCSK9). PCSK9 adalah protein yang menargetkan reseptor LDL untuk degradasi; penghambatannya meningkatkan kemampuan hati untuk menghilangkan LDL-C, yang sering disebut sebagai kolesterol "jahat", dari darah.<ref>{{cite journal | vauthors = Coppinger C, Movahed MR, Azemawah V, Peyton L, Gregory J, Hashemzadeh M | title = A Comprehensive Review of PCSK9 Inhibitors | journal = Journal of Cardiovascular Pharmacology and Therapeutics | volume = 27 | pages = 10742484221100107 | date = 20 May 2022 | pmid = 35593194 | doi = 10.1177/10742484221100107 | s2cid = 248918656 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Weinreich M, Frishman WH | title = Antihyperlipidemic therapies targeting PCSK9 | journal = Cardiology in Review | volume = 22 | issue = 3 | pages = 140–146 | date = 2014 | pmid = 24407047 | doi = 10.1097/CRD.0000000000000014 | s2cid = 2201087 }}</ref>
| |||